Beren Therapeutics
- Health & Biotech
- Thousand Oaks, CA, US
- Founded 2019
- Private
- berentx.com
Clinical-stage biotech developing adrabetadex for infantile-onset Niemann-Pick disease type C and other disorders of cholesterol trafficking.
$135MEquity raised in 2025–20262025 — · 2026 $135M · 1 equity round
$135MEquity raised, all time1 equity round sourced so far
—Latest valuationnot disclosed
$165MDebt financingnot counted as equity · all in 2025–2026
Rounds over time log-scaled amounts
Funding history 2 rounds · 3 sources · newest first
Earlier rounds not yet sourced. Beren Therapeutics was founded in 2019 and raised before 10 Jun 2026; only the rounds below are sourced so far, so its all-time equity total understates its history.
- Hercules Capital debt and royalty financingDebt · not equityAmount$165MPost-money—✓ Confirmed
- Equity financingAmount$135MPost-money—✓ Confirmed
- Earlier rounds not yet sourced
Investors 5
- Eisai
- Founders Fund
- JIC Venture Growth Investments
- Narya Capital
- Wellington Partners
Highlighted investors led at least one equity round; the number is equity rounds taken part in.
Lenders and secondary buyers 1
- Hercules CapitalDebt · lead
Took part only in debt or secondary rounds, so they are not counted as investors and draw no links on the globe.
Related companies shared investors
Anduril IndustriesDefense · $7.5B in 2025–2026Shared: Founders FundCrusoeAI Infra · $5.3B in 2025–2026Shared: Founders FundRampFintech · $3.6B in 2025–2026Shared: Founders FundCognitionAI Apps · $3.4B in 2025–2026Shared: Founders FundHadrianDefense · $1.8B in 2025–2026Shared: Founders FundImpulse SpaceDefense · $1.1B in 2025–2026Shared: Founders Fund
Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Beren Therapeutics and its logo are trademarks of their owners, used here for identification only.
